FDA has decided not to move forward with a 2016 proposal that would have required makers of many class II and III devices intended for use in patients' homes to submit labeling and package inserts in electronic form to the agency.
"FDA does not plan to finalize the 2016 proposal," the agency announces in the US Department of Health and Human Services Fall 2018 Unified Agenda of Federal Regulatory and Deregulatory Actions, posted online Oct. 17. The reversal comes after extensive pushback from device companies.
The electronic submissions would have formed the basis of an FDA-administered public database of home-use device labeling and instructions. It was intended as a resource for patients and caregivers to enhance device safety in the home environment. (Also see "Electronic Labeling Submissions Proposed For Home-Use Devices" - Medtech Insight, 18 Oct, 2016.)
But device-makers argued that the mandatory e-submissions would be unnecessarily onerous and cause more confusion that benefit for patients. Companies said in comments submitted in response to the 2016 proposed rule that the mandatory effort would be redundant to labeling information already provided on manufacturer websites. (Also see "FDA Home-Use e-Labeling Proposal Gets Serious Pushback From Medtech Firms" - Medtech Insight, 26 Jan, 2017.)
The Unified Agenda also signaled that FDA may soon finalize another rule that made industry nervous in the proposal phase.
The agency says that a 2014 proposed rule on "medical device classification procedures" is on tap to be finalized in November. Ostensibly, the rule is intended to implement provisions of the 2012 FDA Safety and Innovation Act that require FDA to reclassify devices using administrative orders rather than formal, and more time-consuming, regulations.
But the 2014 proposal also included more prescriptive language to explain what types of devices should be designated to the most significantly regulated class III category and are not suitable for down-classification. (Also see "What Makes A Device Class III? FDA Proposes New Language To Clarify" - Medtech Insight, 24 Mar, 2014.) Device industry groups said the proposed language, if finalized, would lead to more devices requiring PMAs to enter the US market. (Also see "More PMAs Would Result From FDA’s Classification Proposed Reg, AdvaMed Warns" - Medtech Insight, 23 Sep, 2014.)
FDA could finalize the rule with similar wording to the proposal or it could make substantive changes in response to the industry comments.
HHS' fall agenda includes other FDA medical device regulations as well, including several that have been on the agency's list for some time and others that are newer additions. Here is a sampling of noteworthy proposed and final rules to look out for, including planned release dates:
De novo rule this month? A proposed rule to map out the process forde novo classifications could see the light of day as early this month, following an FDA guidance issued in 2017 detailing updates to the program for low- to- moderate-risk devices with no predicate. (Also see "De Novo Policies Clarified In Final Guidance" - Medtech Insight, 1 Nov, 2017.) (Proposed rule; October 2018)
No more quarterly PMA and HDE listings: FDA plans to propose amended regulations that would end its quarterly listings of PMA and humanitarian device exemption approvals to improve efficiency and eliminate duplication. (Proposed rule; June 2019)
Amending and repealing device software regulations: A proposed rule could be issued as early as November to implement the 21st Century Cures provisions to exclude certain medical software functions from the definition of a medical device. (Also see "US FDA Asks For Public Input On Software It Can't Regulate" - Medtech Insight, 29 May, 2018.) (Proposed rule; November 2018)
Supervisory review final rule: The agenda suggests FDA plans to finalize its January 2018 proposed rule explaining the supervisory review and appeals process for devices by June 2019. (Also see "Appealing An FDA Device Decision? Proposed Rule Clarifies Framework" - Medtech Insight, 18 Jan, 2018.) (Final rule; June 2019)
Harmonizing QSR and ISO 13485: FDA's previously announced plan to harmonize its Quality System Regulation with the global ISO 13485 quality standard is slated to come out in proposed rule form in September 2019, according to the latest agenda. (Also see "QSR Author Kim Trautman Predicts What A Mash-Up Of FDA's Quality System Regulation And ISO 13485 Might Look Like" - Medtech Insight, 15 Aug, 2018.) (Proposed rule; September 2019)
Anthrax Dx classification: FDA's plan to designate IVDs for detection ofBacillus species as class II devices is on the road to possible finalization next March, according to the agenda. This would be about eight years since the agency originally proposed classification for the tests intended to aid in the diagnosis of anthrax and related diseases. (Also see "Regulatory Briefs: What's New From FDA" - Medtech Insight, 23 Nov, 2015.) (Final rule; March 2019).
From the editors of The Gray Sheet
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: